Compare BKU & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | AAPG |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2011 | 2025 |
| Metric | BKU | AAPG |
|---|---|---|
| Price | $45.13 | $29.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $42.73 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.0M | 3.8K |
| Earning Date | 01-21-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 44.85 | N/A |
| EPS | ★ 3.54 | N/A |
| Revenue | ★ $1,016,093,000.00 | $54,524,554.00 |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $5.73 | $368.64 |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $28.21 | $16.50 |
| 52 Week High | $46.92 | $48.45 |
| Indicator | BKU | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 41.60 |
| Support Level | $45.33 | $28.22 |
| Resistance Level | $46.33 | $29.50 |
| Average True Range (ATR) | 0.94 | 0.86 |
| MACD | -0.11 | -0.10 |
| Stochastic Oscillator | 44.89 | 26.83 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.